• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Annexon Bio To Present At TD Cowen Health Care Conference

    GLOBENEWSWIRE

    Annexon Hosts KOL Event On Vonaprument For Geographic Atrophy

    GLOBENEWSWIRE

    Annexon Advances Immunotherapy For Neuroinflammatory Diseases

    GLOBENEWSWIRE

    Annexon Seeks EMA Approval For Guillain-Barré Syndrome

    GLOBENEWSWIRE

    Annexon Bio To Present At J.P. Morgan Healthcare Conference

    GLOBENEWSWIRE

    Annexon Plans Public Stock Offering With Pre-Funded Warrants

    GLOBENEWSWIRE

    Annexon Joins EMA Pilot for Vonaprument in Dry AMD

    GLOBENEWSWIRE

    Annexon Completes Enrollment for Phase 3 Trial for Dry AMD

    GLOBENEWSWIRE

    Annexon Appoints Retina Expert as ANX007 Trial Advances

    GLOBENEWSWIRE

    Annexon to Present Neuroprotective Effects of ANX007 at 2025 ARVO

    GLOBENEWSWIRE

    Annexon`s Leadership in GBS Research at AAN 2025 Meeting

    GLOBENEWSWIRE

    Annexon Reports Q4 & FY24 Results, Highlights Key Milestones

    GLOBENEWSWIRE

    Annexon`s ANX007 Differentiation in Geographic Atrophy at Meeting

    GLOBENEWSWIRE

    Annexon Presents ARCHER Data on ANX007 in Geographic Atrophy

    GLOBENEWSWIRE

    Annexon To Present Phase 2 ARCHER Data For ANX007 In Dry AMD

    GLOBENEWSWIRE

    Annexon To Present Phase 2 ARCHER Data

    GLOBENEWSWIRE

    Annexon Presents Positive Phase 3 Results for ANX005 in Guillain-Barré Syndrome

    GLOBENEWSWIRE

    Annexon To Present ANX005 Phase 3 Data In Guillain-Barré Syndrome At PNS 2024

    GLOBENEWSWIRE

    Annexon: Positive Phase 3 Results For ANX005 In Guillain-Barré Syndrome

    GLOBENEWSWIRE

    Annexon Vision Protection Data for ANX007 in Geographic Atrophy at ARVO

    GLOBENEWSWIRE

    Annexon: ARVO Data On ANX007 Neuroprotection In Geographic Atrophy

    GLOBENEWSWIRE

    Annexon Outlines Global Registrational Program for ANX007

    GLOBENEWSWIRE

    Annexon Receives PRIME Designation from the EMA for ANX007

    GLOBENEWSWIRE

    Annexon Announces Clinical and Regulatory Progress for ANX005 Program

    GLOBENEWSWIRE

    Annexon Presents ARCHER Trial Results at ASRS Highlighting Potential of ANX007

    GLOBENEWSWIRE

    Annexon eye disease med failed phase 2 goal—the CEO is thrilled

    FIERCE BIOTECH

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.